Polymeric Nanoparticle Delivery of EGFR Ligands for Cartilage Protection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for osteoarthritis lack disease-modifying therapies, and existing delivery methods for growth factors like TGFα have limited joint retention and penetration, making them ineffective in preventing OA progression and joint pain.

Innovation Solution

Development of therapeutic compositions comprising polymeric nanoparticles conjugated with EGFR ligands such as TGFα, which are designed to have a specific surface charge for enhanced interaction with cartilage, allowing for targeted delivery and prolonged retention in the joint, thereby activating the EGFR pathway to protect cartilage from degeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If growth factors like TGFα are used to treat osteoarthritis, then cartilage protection is achieved, but joint retention and penetration are limited

Engineering Contradiction:

Improvecartilage protectionVSAvoidjoint retention

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent uses polymeric nanoparticles as an intermediary carrier to deliver TGFα ligands into the joint. These nanoparticles mediate between the growth factor and the cartilage tissue, enabling prolonged retention and effective penetration while maintaining cartilage protection effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the physical and chemical parameters of the growth factor delivery system by conjugating TGFα to polymeric nanoparticles with specific surface charges (−5 to 30 mV). This parameter change enhances interaction with cartilage and improves both penetration and retention characteristics.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If growth factors like TGFα are used to treat osteoarthritis, then cartilage protection is achieved, but penetration into cartilage is limited

Engineering Contradiction:

Improvecartilage protectionVSAvoidpenetration depth

Core Design Contradiction:

ReliabilityVSLength of moving object

Solution Approach 1:

Polymeric nanoparticles serve as an intermediary vehicle that facilitates deep penetration of TGFα ligands into cartilage tissue. The nanoparticle carrier enables the growth factor to traverse the cartilage matrix more effectively than free ligands alone.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent optimizes nanoparticle parameters including size, surface charge (−5 to 30 mV), and material composition to enhance penetration depth. These parameter adjustments allow the delivery system to effectively reach deep cartilage regions while maintaining ligand activity.

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If existing delivery methods are used for growth factors, then administration is simple, but therapeutic effectiveness is insufficient

Engineering Contradiction:

Improveadministration simplicityVSAvoidtherapeutic effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The polymeric nanoparticle serves as an intermediary that maintains the simplicity of intrarticular injection administration while dramatically improving therapeutic effectiveness. The nanoparticle carrier system preserves ease of administration through simple injection while enabling sustained ligand release and targeted delivery.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The nanoparticle-based delivery system effectively attenuates OA progression and joint pain by maintaining cartilage integrity and reducing subchondral bone sclerosis, with no detectable side effects on major organs or joint structure.

Implementation Method 1

The nanoparticle is injected into a joint of a subject in need thereof

Methodology Applied

Scientific EffectDiffusion: Diffusion

Implementation Method 2

The nanoparticle is injected into a joint of a subject in need thereof

Methodology Applied

Scientific EffectAdvection: Advection

Implementation Method 3

a ligand selected to activate an EGFR receptor

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 4

activating the EGFR pathway to protect cartilage from degeneration

Methodology Applied

Scientific EffectSignal transduction:

Implementation Method 5

designed to have a specific surface charge for enhanced interaction with cartilage

Methodology Applied

Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentUS20230310647A1Targeting cartilage EGFR pathway for osteoarthritis treatment

Publication Date: 2023.10.05 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

AI summary

Provided are therapeutic compositions, comprising: a polymeric nanoparticle; a ligand selected to activate an EGFR receptor; and a linker, the linker associating the nanoparticle and the ligand. Also provided are therapeutic compositions, comprising: a nanoparticle; a ligand, the ligand being any one of EGF, transforming growth factor-alpha (TGFα), heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), epiregulin (EREG), or epigen; and a linker associating the nanoparticle and the ligand, the therapeutic composition having a surface charge in the range of from about −5 to about 30 mV. Related methods of treatment are also provided.